Why Ptc Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday

In biotech, what goes around comes around.Yesterday, PTC Therapeutics (NASDAQ: PTCT) jumped 27.5% following positive data for its spinal muscular atrophy drug, risdiplam, which sent shares of competitors Biogen and Ionis Pharmaceuticals down on the news.Today, it was PTC Therapeutics' turn to take a hit, falling 30.6% today, after competitor Sarepta Therapeutics (NASDAQ: SRPT) presented data for its gene therapy to treat Duchenne muscular dystrophy (DMD).Continue reading

BING NEWS:
  • PTC Therapeutics Inc.
    The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
    03/27/2024 - 1:01 pm | View Link
  • PTC Therapeutics, Inc.: PTC Therapeutics Provides Key Regulatory Updates
    2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the submission of a BLA to the U.S. FDA for Upstaza (eladocagene exuparvovec), a gene therapy for the treatment of ...
    03/19/2024 - 1:30 am | View Link
  • PTC Therapeutics Breaks Above 200-Day Moving Average
    In trading on Friday, shares of PTC Therapeutics Inc (Symbol: PTCT) crossed above their 200 day moving average of $32.01, changing hands as high as $32.91 per share. PTC Therapeutics Inc shares ...
    03/1/2024 - 8:38 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News